Dermatology
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Novartis’s ianalumab, for treating Sjögren’s disease, is also among the new drugs that the European Medicines Agency has started reviewing for potential pan-EU marketing approval.
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
With the ongoing launch of the chronic hand eczema therapy, and the addition of Spevigo, the Danish group has entered 2026 with strong momentum, its CEO Christophe Bourdon tells Scrip.
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
The US biotech has upsized its public offering to $175m after the success of soquelitinib in a very early trial for atopic dermatitis.
The inflammatory skin disease typically affects the anogenital area and the Denmark-headquartered firm has started a Phase III trial evaluating its chronic hand eczema in that space.
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Sun launches tildrakizumab, its star psoriasis therapy in India seven years after US FDA approval at what’s seen as a carefully calibrated price point. Can it ruffle entrenched products like secukinumab?
The European Medicines Agency has begun evaluating the EU marketing applications for a new batch of drugs, including products from Incyte, Sanofi and Novo Nordisk that target hidradenitis suppurativa, rabies and hemophilia A, respectively.
While the European Medicines Agency’s human medicines committee voted in favor of EU approval for 10 new products, it reaffirmed its previous decision not to grant Aqneursa new active substance status.